Beyond Remission. Toward Functional Cure.

Current thyroid cancer therapies are effective—but incomplete.

They target single pathways, allowing the disease to adapt through:

• Metabolic reprogramming
• Immune exhaustion
• Neuroendocrine stimulation
• Microenvironmental escape

SCF-PCR™ redefines treatment:

→ A systems-level, multi-axis therapeutic strategy designed to eliminate disease persistence and prevent recurrence

What is SCF-PCR™?

The SCF-PCR (Preventative–Curative–Restorative) model is a precision-engineered therapeutic architecture that integrates:

Powered by FDA-Approved Therapeutics

SCF-PCR™ is built for immediate clinical translation, leveraging:

• Targeted therapies

(e.g., lenvatinib, BRAF/MEK inhibitors, RET inhibitors)

• Immunotherapies (AEGIS-controlled)

(e.g., pembrolizumab, nivolumab)

• Metabolic modulators

(e.g., metformin)

• Neuroendocrine regulators

(e.g., levothyroxine, propranolol)

→ No dependency on novel drugs—only smarter, synergistic use of existing ones

Multi-Axis Therapeutic Engine

SCF-PCR™ simultaneously targets the full disease system:

→ Multi-axis pressure prevents resistance before it starts

AEGIS-RVL™: Immune Control Without Exhaustion

Traditional immunotherapy often leads to immune burnout.

SCF-PCR™ integrates AEGIS-RVL™, an adaptive immune control system:

• Activation Phase → Engage immune response
• Sustainment Phase → Maintain tumor targeting
• Recovery Phase → Prevent T-cell exhaustion

→ Continuous effectiveness without immune collapse

Synergistic Augmentation (1 + 1 ⇒ 3)

SCF-PCR™ is not combination therapy—it is engineered synergy:

• Signal + Metabolic → Blocks growth + removes energy
• Metabolic + Immune → Enhances T-cell performance
• Neuro + Immune → Restores immune efficiency
• Targeted + Cytotoxic → Ensures irreversible tumor kill

→ Amplified therapeutic impact beyond additive effects

Designed for Functional Cure

SCF-PCR™ targets all known drivers of recurrence:

• Residual tumor cells
• Immune escape mechanisms
• Metabolic survival pathways
• Neuroendocrine stimulation

Functional Cure Goal

• No detectable disease (imaging + molecular)
• Sustained immune competence
• No progression without continuous therapy

Stage-Specific Precision

SCF-PCR™ adapts to disease progression:

Early Stage

• TSH suppression
• Targeted therapy (if mutation-driven)

RAI-Refractory

• Targeted therapy + metabolic modulation

Advanced / Metastatic

• Full multi-axis SCF-PCR™ stack
• AEGIS-controlled immunotherapy
• Cytotoxic augmentation (select cases)

Built-In Safety & Control

• Adaptive dosing (biomarker-guided)
• Immune cycling (prevents toxicity)
• Staggered multi-drug scheduling
• Continuous system monitoring

→ Precision control replaces continuous high-dose exposure

Why SCF-PCR™

• System-Level Approach — not single-target therapy
• FDA-Aligned — built entirely on approved drugs
• Resistance-Aware — multi-axis suppression
• Immune-Protective — prevents exhaustion
• Clinically Scalable — ready for trial translation

Development Pathway

Current Status

• SCF-PCR architecture validated
• FDA-approved drug mapping completed
• IND-enabling framework established

1. IND-Enabling Studies

• Combination safety and PK/PD
• Immune biomarker validation (AEGIS-RVL™)

3. Phase II Expansion

• Mutation-stratified cohorts
• Comparative efficacy vs standard of care

2. First-in-Human Adaptive Trial

• Real-time biomarker-guided dosing
• Multi-axis response evaluation

4. Platform Expansion

• Extension to additional solid tumors
• Immune-exhaustion-driven disease models